ReviewMethods in molecular biology (Clifton, N.J.)2026
The Role of EBV Infection and Epigenetic Factors in Radioresistance of Colorectal Cancer.
Review in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite great progress made in therapeutic strategies, the 5-year survival rate of colorectal cancer (CRC) remains low due to the high incidence rate and mortality. A pivotal factor in treatment failure is radioresistance-the ability of CRC cells to withstand high doses of ionizing radiation (IR). Understanding the cellular and molecular mechanisms that underline radiation resistance as well as characteristics of radioresistant cells is particularly warranted for exploiting novel treatment modalities. In the context of combating radioresistance in CRC, potential targets of interest include Epstein-Barr virus (EBV), microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and their related signaling pathways amenable to pharmacological intervention. Additionally, radiotherapy reprograms the tumor microenvironment that has impacts on innate and adaptive immunity, such as recruitment of cancer-associated fibroblasts (CAFs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). Targeting these immunosuppressive cells has the potential to enhance treatment responses in patients with radioresistant CRC. This review endeavors to depict a comprehensive landscape of factors influencing radiosensitivity of CRC, paving the way for advancements in future clinical applications.
Indexed as
Identifiers
42108297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.